Could the GI tract be a better portal for antibody therapy?

Comment

S J Green et al. Gut. 2006 Nov.

. 2006 Nov;55(11):1681-2.

No abstract available

Conflict of interest statement

Conflict of interest: None declared.

A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease.
Reinisch W, Hommes DW, Van Assche G, Colombel JF, Gendre JP, Oldenburg B, Teml A, Geboes K, Ding H, Zhang L, Tang M, Cheng M, van Deventer SJ, Rutgeerts P, Pearce T. Reinisch W, et al. Gut. 2006 Aug;55(8):1138-44. doi: 10.1136/gut.2005.079434. Epub 2006 Feb 21. Gut. 2006. PMID: 16492717 Free PMC article. Clinical Trial.

1. Ochi H, Abraham M, Ishikawa H. Oral CD3‐specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+CD25‐LAP+ T cells. Nat Med 200612527–635. - PubMed
1. Chatenoud L. Weaned from the needle. Nat Med 200612617 - PubMed
1. Petschow B W, Talbott R D. Reduction in virus‐neutralizing activity of a bovine colostrum immunoglobulin concentrate by gastric acid and digestive enzymes. J Pediatr Gastroenterol Nutr 199419228–235. - PubMed
1. Tacket C O, Losonsky G, Link G.et al Protection by milk immunoglobulin concentrate against oral challenge with enterotoxigenic Escherichia coli. N Engl J Med 19983181240 - PubMed
1. Zeitlin L, Cone R A, Whaley K J. Using monoclonal antibodies to prevent mucosal transmission of epidemic infectious diseases. Emerg Infect Dis 1999554–64. - PMC - PubMed